Skip to main content
Isofol Medical logo

Isofol Medical — Investor Relations & Filings

Ticker · ISOFOL ISIN · SE0009581051 LEI · 549300MCXYAHG7VBHX75 ST Professional, scientific and technical activities
Open in API
Filings indexed 208 across all filing types
Latest filing 2023-05-03 Report Publication Anno…
Country SE Sweden
Listing ST ISOFOL

About Isofol Medical

https://isofolmedical.com/

Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2023
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the publication of the company's Q1 2023 interim report. It contains a summary of key financial highlights (net sales, profit, cash position) and significant events, but explicitly states that the full report is available on the company's website. Given the document length (approx. 4,400 characters) and its function as an announcement of a report release rather than the full report itself, it falls under the 'Report Publication Announcement' category. Q1 2023
2023-05-03 Swedish
Report Publication Announcement 2023
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the publication of an interim report. It is under 5,000 characters and explicitly states that the full interim report is available on the company's website. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the interim report itself. Q1 2023
2023-05-03 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding and voting rights for a specific instrument (Aktier/Shares) held by Avanza Bank Holding AB for its pension subsidiary. It explicitly lists the 'Quantity' of shares held (16,303,944) and the resulting 'Percentage of voting rights' (10.09436 %). This structure—reporting transactions by an insider or major shareholder that cross a specific threshold (implied by the detailed reporting)—is characteristic of a Major Shareholding Notification. The filing type code 'MRQ' (Major Shareholding Notification) fits this content best, as it reports changes in significant ownership levels.
2023-04-27 English
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-04-06 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-04-06 Swedish
Kallelse till årsstämma den 3 maj 2023 i Isofol Medical AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Kallelse till årsstämma den 3 maj 2023 i Isofol Medical AB (publ)" which translates to "Notice of Annual General Meeting on May 3, 2023 in Isofol Medical AB (publ)". It details the date, time, location, registration procedures, and the proposed agenda for the Annual General Meeting (AGM), including proposals for board elections, remuneration, and profit distribution. This content directly corresponds to the definition of AGM Information, which is classified as AGM-R.
2023-04-03 Swedish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.